BSNL forays into 5G fixed wireless service
New Delhi: State-owned telecom firm
BSNL
has forayed into 5G fixed wireless service to provide home broadband service with its launch in Hyderabad, the company said on Friday.
At present, Reliance Jio and
Bharti Airtel
have been providing 5G Fixed Wireless Service (FWA) by using their 5G spectrum.
"
Quantum 5G FWA
demonstrates how Indian engineers can create world-class connectivity. It is the first SIM-less, 100 per cent home grown customised 5G FWA for BSNL. Today is only a soft launch - many more cities and feature upgrades will follow," BSNL Chairman and Managing Director A Robert J Ravi said.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
How Much Should You Pay A Cleaner To Clean Your Apartment in Vietnam?
Cleaning | Search Ads
Search Now
Undo
The service was launched on June 18.
According to the details shared by BSNL, the company will expand the pilot project in Bengaluru, Pondicherry, Vishakhapatnam, Pune, Gwalior and Chandigarh by September 2025.
Live Events
The company is initially charging Rs 999 for a 100 megabit per second (mbps) plan and Rs 1,499 for a 300 mbps plan.
Through 5G FWA, telecom operators install a modem outside the subscriber's premise and transmit signals from their nearest base station for wireless broadband service.
The technology does not require optical fibre for connection.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
23 minutes ago
- Time of India
Lauritz Knudsen unveils expanded product portfolio to support India's industrial growth
Lauritz Knudsen Electrical and Automation has announced the launch of its most extensive product portfolio to date, focused on India's industrial clusters and infrastructure corridors. The company has also initiated a 30-city 'Technology Tour' to demonstrate new solutions and engage with local industry stakeholders. The initiative includes new offerings in low-voltage systems , industrial automation , and energy infrastructure . According to the company, the aim is to develop technology that aligns with the specific requirements of different Indian regions, while contributing to national goals under the Viksit Bharat 2047 vision. Regional approach and sectoral engagement Naresh Kumar, Chief Operating Officer at Lauritz Knudsen, said: 'At Lauritz Knudsen, our purpose is to deliver smart technologies that empower customers to work safer, faster, and smarter. Through this product showcase, we are reinforcing our belief that innovation must be accessible, adaptable, and relevant to the unique needs of every region across India. Whether it's automating a rice mill in Raipur, powering a textile mill in Coimbatore, or modernizing a plant in Pune, our portfolio is designed for impact.' The product line-up includes: EV Charging Ecosystem – Comprising EV chargers, a centralised charge management system (CMS), and cloud-based Power Distribution Architecture – New air circuit breakers and moulded case circuit breakers (MCCBs) designed for integration with digital Automation Solutions – Variable frequency drives, PLCs, and HMIs with IoT-enabled control via Smartcomm Numerical Protection Relays – For low and medium voltage systems, providing control and communication functions. Commenting on sector trends, Kumar noted: 'With India's electrical equipment sector projected to grow by over USD 95 billion by 2029 and industrial automation expected to reach USD 39.65 billion by 2033, the momentum is clear. Indian manufacturers are already investing 35% of their operating budgets into tech modernization—well above the global average. These shifts are not just numbers; they reflect a nationwide drive toward smarter, more efficient systems.' Lauritz Knudsen plans to showcase its portfolio in industrial cities such as Pune, Noida, Bhubaneswar, Coimbatore, and Guwahati, targeting regional manufacturing and infrastructure clusters. The company described itself as a strategic enabler for inclusive and sustainable growth, aiming to support India's efforts in clean energy, agricultural efficiency, and industrial modernisation.
Time of India
25 minutes ago
- Time of India
Altimmune's stock plummets over 60% as liver drug falls short in trial
Altimmune's stock (NASDAQ: ALT) plunged roughly 60–64% in pre-market trading today after it announced mixed results from its mid-stage (IMPACT Phase 2b) trial evaluating its liver drug, pemvidutide , for metabolic dysfunction-associated steatohepatitis (MASH). The drug showed promising results in reducing liver fat and achieving MASH resolution, but failed to deliver strong statistical evidence for fibrosis improvement—a key benchmark in this disease area. What is the current stock price of Altimmune? As of June 26, 2025 , Altimmune is trading at $7.71 per share . This price represents a significant pullback from its recent highs, though it remains above its 52-week low. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Join new Free to Play WWII MMO War Thunder War Thunder Play Now Undo Current price: $7.71 52-week high: $11.16 52-week low: $3.55 Market cap: Estimated between $558 million to $625 million Also Read: US stock futures rise: Dow, S&P 500, and Nasdaq edge higher as Nvidia, BlackBerry, and QuantumScape rally Did pemvidutide meet its primary endpoint? Yes. The trial hit its primary goal: resolution of MASH without worsening liver fibrosis. At 24 weeks: Live Events 59.1% of patients on the 1.2 mg dose saw MASH resolution 52.1% achieved resolution on the 1.8 mg dose Only 19.1% on placebo met this benchmark These results were statistically significant and well above expectations, positioning pemvidutide as a serious contender in the MASH space. Also Read: Intel layoffs 2025: Design engineers, software architects lose jobs - these key divisions are next What about weight loss and secondary benefits? Altimmune also highlighted significant weight loss among trial participants: 5.0% weight loss at 1.2 mg 6.2% at 1.8 mg , compared to 1.0% in placebo This positions pemvidutide alongside other GLP-1 class weight-loss drugs, a category currently generating high investor and consumer interest. Why did the stock crash despite positive results? The issue lies with the fibrosis endpoint. While there were improvements, the trial didn't reach statistical significance in its primary analysis of fibrosis reduction—a major goal in MASH treatment. Though an AI-assisted analysis showed 30.6% of patients had ≥60% reduction in fibrosis (vs. 8.2% placebo), it wasn't enough to reassure investors looking for definitive progress in this area. Are analysts still bullish on Altimmune? Yes, despite the sell-off, Wall Street remains optimistic about Altimmune's long-term prospects. The stock currently holds a "Strong Buy" rating from analysts. That suggests potential upside of nearly 190% from the current price level, assuming pemvidutide regains investor confidence in later trials. What are the short-term stock trends for ALT? Technically, ALT has been highly volatile and is currently trading in the mid-range of its 52-week band . Short-term charts show neutral-to-bearish signals , with some analysts recommending caution until the stock finds support or stabilizes. What is MASH treatment? MASH, short for Metabolic dysfunction-associated steatohepatitis, is the new name for what was previously called NASH (Non-Alcoholic Steatohepatitis). It's a serious form of fatty liver disease that occurs when fat builds up in the liver and causes inflammation and liver cell damage, potentially leading to fibrosis, cirrhosis, or even liver cancer. What's next for Altimmune and pemvidutide? Altimmune will hold an investor webcast to discuss results and plans to meet the FDA for an End-of-Phase 2 meeting by late 2025. A Phase 3 trial is still under consideration. FAQs: What caused Altimmune stock to crash after the MASH trial? The stock crashed after its MASH drug failed to show strong results in improving liver fibrosis. Is Altimmune still moving forward with pemvidutide? Yes, the company plans to meet the FDA and may start a Phase 3 trial.
Time of India
25 minutes ago
- Time of India
Invicta Diagnostic raises Rs 6 crore in pre-IPO round
Mumbai-based Invicta Diagnostic on Thursday said it has raised Rs 6 crore from marquee investors in its pre-IPO funding round. The funding round was led by Grobiz SME Opportunities Fund with participation from prominent angel investors, the company said in a statement. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Ingin Tahu Tentang Diagnosis Limfoma? Dapatkan Info Selengkapnya Limfoma Baca Undo Invicta Diagnostic provides a one-stop solution for pathology and radiology testing services , including imaging and clinical laboratory. It has seven diagnostic centres and one centralised laboratory across the Mumbai Metropolitan Region. It offers comprehensive radiology and pathology solutions under the brand name 'PC Diagnostics'.
